Target Disease

Pain

Why This Disease Focus?

Pain is a common and potentially debilitating condition affecting around one-quarter of the global population. While some effective medicines exist, they can come with significant side effects, including risk of addiction.

Goal of Program

Endocannabinoid regulation

Outside the U.S., ONO is exploring this endocannabinoid regulator as a potential treatment for pain.

*This molecule is not approved by any regulatory authority for any use.

Target Disease

Neurodegenerative disease

Why This Disease Focus?

Neurodegenerative diseases are numerous and have limited therapeutic options, creating a growing global burden.

Goal of Program

Epigenetic regulation

ONO is carrying out a clinical Phase 1 trial in the U.S. to evaluate safety, tolerability, and pharmacokinetics of ONO-2020 in healthy adult participants.

*This molecule is not approved by any regulatory authority for any use.

Target Disease

Multiple system atrophy (MSA)

Why This Disease Focus?

Multiple system atrophy (MSA) is a rare neurological disease that can affect motor control as well as the body’s autonomic functions, including blood pressure regulation. There is currently no FDA-approved treatment for MSA. Most therapies involve managing symptoms.

Goal of Program

S1P5 receptor agonist

ONO is investigating the safety, tolerability, and pharmacokinetics of ONO-2808 in patients with MSA in a Phase 2 trial in the U.S.

*This molecule is not approved by any regulatory authority for any use.

Target Disease

Diabetic polyneuropathy

Why This Disease Focus?

• Polyneuropathy is complication of diabetes. 
• The condition affects the nerves that serve the extremities. Symptoms can include tingling or prickling; numbness or pain in the hands, legs, and feet; muscle weakness; sensitivity to touch; insensitivities to temperature changes or pain; and loss of balance or coordination.

Goal of Program

Enhancement of Schwann cell differentiation

Schwann cells, a type of support cell in the brain, wrap around axons of peripheral nerve cells to form a myelin sheath and support neural function. Research shows that Schwann cells may play a role in the pathogenesis of various polyneuropathies. Outside the U.S., ONO-2910, which may affect Schwann cell differentiation, is being investigated in diabetic polyneuropathy.

*This molecule is not approved by any regulatory authority for any use.

Target Disease

Chemotherapy-induced peripheral neuropathy

Why This Disease Focus?

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy. It has become more prevalent as cancer treatments have become more effective over the years and people are living longer.

Goal of Program

Enhancement of Schwann cell differentiation

Schwann cells, a type of support cell in the brain, wrap around axons of peripheral nerve cells to form a myelin sheath and support neural function. Outside the U.S., ONO-2910, which may affect Schwann cell differentiation, is being investigated for CIPN.

*This molecule is not approved by any regulatory authority for any use.